FDA Anti-Counterfeit Technology Policy Head Is Ex-CMS Staffer Rudolf
Executive Summary
FDA's development of a policy on technology-based anti-counterfeiting efforts will be overseen by Senior Advisor for Medical & Health Policy Paul Rudolf, MD
You may also be interested in...
FDA Economist Lutter To Head Policy & Planning Office After Hubbard Retires
FDA is announcing a leadership succession plan for the Office of Policy & Planning ahead of the impending retirement of Associate Commissioner William Hubbard
FDA Economist Lutter To Head Policy & Planning Office After Hubbard Retires
FDA is announcing a leadership succession plan for the Office of Policy & Planning ahead of the impending retirement of Associate Commissioner William Hubbard
FDA Counterfeit Drug Website “Icon” Considered For Education Campaign
The FDA Counterfeit Drug Task Force's public education subcommittee may develop an "icon" that would allow anti-counterfeiting collaborators' websites to link to an online FDA reference page